Notice Number: NOT-HL-18-644
Key Dates
Release Date: August 2, 2018
Issued by
National Heart, Lung, and Blood Institute (NHLBI)
Purpose
The purpose of this Notice is to inform potential applicants that NHLBI’s TOPMed program has a strong interest in receiving applications on sickle cell and other rare blood disorders such as bone marrow failures and hemophilia, in response to PAR-16-021, "NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01)". Applicants are encouraged to propose other ‘omics’ including microbiome measurements to address a specific hypothesis.
Applicants are strongly encouraged to review the Frequently Asked Questions, which may be updated at any time without additional notice.
Inquiries
Please direct all inquiries to:
Pankaj Qasba, Ph.D.
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0050
Email: qasbap@nhlbi.nih.gov